AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11507356 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (OAT group)
Number of subjects: 120
Study 11507356 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole resistance
Number of subjects: 120
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: One layer of cotton gloves
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Two layers of cotton and rubber gloves
Number of subjects: 40
Study 9414378 — intervention group
Group type: COMPARATOR
Intervention: Barehanded condition
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating height at shoulder
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating height at elbow
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating height overhead
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwheel diameters ranging from 75 to 95 mm for males
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwheel diameters ranging from 65 to 80 mm for females
Number of subjects: 40
Study 9414378 — intervention group
Group type: EXPERIMENTAL
Intervention: Average R/U MVTE for females
Number of subjects: 40
Study 8499376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ablation-zone PRK
Number of subjects: 24
Study 8499376 — intervention group
Group type: COMPARATOR
Intervention: Double ablation-zone PRK
Number of subjects: 24
Study 6233550 — intervention group
Group type: EXPERIMENTAL
Intervention: Blo-Bag with Duovent metered dose inhaler
Number of subjects: 0
Study 6233550 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhaler alone
Number of subjects: 0
Study 31436839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate, 625 mg, twice daily
Number of subjects: 35
Study 31436839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate, 1250 mg, twice daily
Number of subjects: 35
Study 29549533 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported RP-related symptoms during the last week of CRT
Number of subjects: 132
Study 29549533 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe patient-rated RP-related symptom score (≥ 4 on a 0-10 scale)
Number of subjects: 132
Study 29549533 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-lung FDG uptake (SUVmean > 0.78)
Number of subjects: 132
Study 27002446 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered self-expandable metallic stents (cSEMS)
Number of subjects: 112
Study 27002446 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 112
Study 25313756 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 62
Study 25313756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 62
Study 22374335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic algorithms derived from Asian patients
Number of subjects: 282
Study 22374335 — intervention group
Group type: COMPARATOR
Intervention: Pharmacogenetic algorithms derived from Caucasian patients
Number of subjects: 282
Study 22374335 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms with additional covariates of INR values
Number of subjects: 282
Study 22374335 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms with additional covariates of CYP4F2*3
Number of subjects: 282
Study 22374335 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms from Caucasian and racially mixed populations
Number of subjects: 282
Study 22374335 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms from Asian populations
Number of subjects: 282
Study 22374335 — intervention group
Group type: EXPERIMENTAL
Intervention: All algorithms
Number of subjects: 282
Study 20586515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 100-250 mg twice daily
Number of subjects: 1030
Study 20586515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone CR 20-50 mg twice daily
Number of subjects: 1030
Study 20586515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 18036103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA); taken by 22 patients
Number of subjects: 27
Study 18036103 — intervention group
Group type: COMPARATOR
Intervention: Pre-UDCA period
Number of subjects: 27
Study 18036103 — intervention group
Group type: COMPARATOR
Intervention: Post-UDCA period
Number of subjects: 27
Study 17901137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound landmarks (ULs)
Number of subjects: 46
Study 17901137 — intervention group
Group type: COMPARATOR
Intervention: Palpation landmarks (PLs)
Number of subjects: 46
Study 17901137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound landmarks (ULs) in obese patients
Number of subjects: 46
Study 17901137 — intervention group
Group type: COMPARATOR
Intervention: Palpation landmarks (PLs) in obese patients
Number of subjects: 46
Study 15168172 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Pik irrigator with subgingival tip (tap water)
Number of subjects: 45
Study 15168172 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Pik irrigator with subgingival tip (herbal mouth rinse)
Number of subjects: 45
Study 15168172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigator or irrigant)
Number of subjects: 45
Study 10751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast solution (40 mg) administered orally
Number of subjects: 5
Study 10751029 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast solution (40 mg) administered via oroenteric tube into the colon
Number of subjects: 5
Study 10751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast solution (40 mg) administered into the distal ileum
Number of subjects: 5
Study 8925829 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ENAL), an angiotensin converting enzyme inhibitor (ACE-I), 5 mg acute administration
Number of subjects: 9
Study 8925829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 9
Study 8925829 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ENAL)
Number of subjects: 9
Study 1336475 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 12
Study 1336475 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy + placebo
Number of subjects: 12
Study 6434285 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 48
Study 6434285 — intervention group
Group type: COMPARATOR
Intervention: Fluid and electrolyte replacement (without TPN)
Number of subjects: 48
Study 6434285 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 48
Study 31769496 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 4712
Study 31769496 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 4712
Study 31769496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4712
Study 31769496 — intervention group
Group type: COMPARATOR
Intervention: Active comparators (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml, dulaglutide 0.75 or 1.5 mg)
Number of subjects: 4712
Study 31136288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2598
Study 28404155 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1057
Study 28404155 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1057
Study 26132642 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 34
Study 26132642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 34
Study 23782429 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (300,000 IU cholecalciferol in oily solution administered seven days pre-operatively)
Number of subjects: 80
Study 23782429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23782429 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 80
Study 21665114 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cetylated fatty ester complex (CFEC) cream application plus physical therapy (CF‐PT)
Number of subjects: 72
Study 21665114 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream application plus physical therapy (PL‐PT)
Number of subjects: 72
Study 19247271 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) 3 days/week
Number of subjects: 16
Study 19247271 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 16
Study 19247271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RT and SED)
Number of subjects: 16
Study 16946605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing proximal lesions with 1 of 2 resins (test group)
Number of subjects: 72
Study 16946605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sealing, only flossing)
Number of subjects: 72
Study 12973509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-thickened infant formula (Nan AR)
Number of subjects: 100
Study 12973509 — intervention group
Group type: COMPARATOR
Intervention: Conventional homemade formula with starch
Number of subjects: 100
Study 10638577 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release 5-ASA suppositories (Pentasa 1 g/day)
Number of subjects: 251
Study 10638577 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5-ASA suppositories (Rowasa 0.5 g b.i.d.)
Number of subjects: 251
Study 8989955 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple semicircular canal occlusion (TCO)
Number of subjects: 8
Study 8989955 — intervention group
Group type: COMPARATOR
Intervention: Labyrinthectomy
Number of subjects: 8
Study 1312757 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase (n = 50/400 ABC‐U/disc)
Number of subjects: 100
Study 1312757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (n = 50/4000 I.U.)
Number of subjects: 100
Study 3850489 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative goal-setting group
Number of subjects: 0
Study 3850489 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider goal-setting group
Number of subjects: 0
Study 3850489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30716669 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway in cancer survivors
Number of subjects: 434
Study 30716669 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported neuropathy in cancer survivors
Number of subjects: 434
Study 30716669 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported falls in cancer survivors
Number of subjects: 434
Study 30716669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral sway in cancer survivors with neuropathy
Number of subjects: 434
Study 30716669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resultant/AP sway frequency in cancer survivors with neuropathy
Number of subjects: 434
Study 30716669 — intervention group
Group type: COMPARATOR
Intervention: Postural sway in healthy control subjects
Number of subjects: 434
Study 29311038 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet
Number of subjects: 146
Study 29311038 — intervention group
Group type: COMPARATOR
Intervention: Conventional Diet
Number of subjects: 146
Study 29311038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 146
Study 26232779 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml/dinner dry red wine
Number of subjects: 54
Study 26232779 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 54
Study 26232779 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml/dinner dry red wine (among fast ethanol metabolizers)
Number of subjects: 54
Study 24447498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose tranexamic acid regimen (loading dose of 10 mg/kg, maintenance dose of 2 mg/kg/h, pump prime dose of 40 mg)
Number of subjects: 175
Study 24447498 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose tranexamic acid regimen (loading dose of 30 mg/kg, maintenance dose of 16 mg/kg/h, pump prime dose of 2 mg/kg)
Number of subjects: 175
Study 22158139 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) during low-intensity resistance exercise (16 minutes, 85 Hz)
Number of subjects: 19
Study 22158139 — intervention group
Group type: COMPARATOR
Intervention: Control condition (low-intensity resistance exercise without WB-EMS)
Number of subjects: 19
Study 20380656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutogliptin 400 mg
Number of subjects: 423
Study 20380656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutogliptin 200 mg
Number of subjects: 423
Study 20380656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 17286343 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic Form 90
Number of subjects: 0
Study 16117574 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy (PRP trial)
Number of subjects: 100
Study 12577349 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and western medicine (TCM-WM) including cardiac diuretics, vasodilative agents, taurine, coenzyme Q10, antiarrhythmics, beta blockers, and Chinese herbal preparations such as Astragalus membranaceus and Shengmai injection.
Number of subjects: 320
Study 12577349 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine alone (control group).
Number of subjects: 320
Study 9713095 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment (Group 1)
Number of subjects: 36
Study 9713095 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous treatment (Group 2)
Number of subjects: 36
Study 8029650 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lignocaine with adrenaline (pH 7.1‐7.3)
Number of subjects: 31
Study 8029650 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine with adrenaline (unbuffered)
Number of subjects: 31
Study 2740841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate in tablets
Number of subjects: 66
Study 2740841 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 66
Study 2740841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate in suspension
Number of subjects: 66
Study 31374049 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoai Jiedu Decoction
Number of subjects: 0
Study 31374049 — intervention group
Group type: COMPARATOR
Intervention: Xiaoai Jiedu Decoction mimetic agent
Number of subjects: 0
Study 28758519 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week perturbed treadmill intervention (n = 21)
Number of subjects: 43
Study 28758519 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22) training on identical treadmill without perturbations
Number of subjects: 43
Study 25458464 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment (2400 mg/day divided into two doses) for 4 weeks
Number of subjects: 21
Study 25458464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC treatment)
Number of subjects: 21
Study 25458464 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment
Number of subjects: 21
Study 23620932 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) and Taichong (LR 3)
Number of subjects: 44
Study 23620932 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupoints (Yanglingquan (GB 34), Yinlingquan (SP 9), Neixiyan (EX‐LE 4), Dubi (ST 35), Zusanli (ST 36))
Number of subjects: 44
Study 21478764 — intervention group
Group type: COMPARATOR
Intervention: 0% body weight assistance (BWA)
Number of subjects: 18
Study 21478764 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% body weight assistance (BWA)
Number of subjects: 18
Study 21478764 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% body weight assistance (BWA)
Number of subjects: 18
Study 21478764 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% body weight assistance (BWA)
Number of subjects: 18
Study 21478764 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% body weight assistance (BWA)
Number of subjects: 18
Study 18239389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiographic examination
Number of subjects: 137
Study 18239389 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (angiotensin II receptor antagonist)
Number of subjects: 137
Study 16820564 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI cell infusion
Number of subjects: 96
Study 16820564 — intervention group
Group type: COMPARATOR
Intervention: AMI control
Number of subjects: 96
Study 16820564 — intervention group
Group type: EXPERIMENTAL
Intervention: OMI cell infusion
Number of subjects: 96
Study 16820564 — intervention group
Group type: COMPARATOR
Intervention: OMI control
Number of subjects: 96
Study 12752749 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan (tablet and nasal spray) and naratriptan (tablet)
Number of subjects: 1932
Study 10828475 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA enemas
Number of subjects: 32
Study 10828475 — intervention group
Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 32
Study 9531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal ketoprofen 30 mg over the proposed surgical area twice (Group 1)
Number of subjects: 60
Study 9531736 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (Group 2)
Number of subjects: 60
Study 9531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal ketoprofen 30 mg over right thigh twice (Group 3)
Number of subjects: 60
Study 8196571 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy
Number of subjects: 1573
Study 8196571 — intervention group
Group type: EXPERIMENTAL
Intervention: Early systemic antifungal treatment
Number of subjects: 1573
Study 3065085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg/day) + bromocriptine (5 mg/day)
Number of subjects: 171
Study 3065085 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen + placebo
Number of subjects: 171
Study 29767330 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Fr Glidesheath Slender
Number of subjects: 200
Study 29767330 — intervention group
Group type: COMPARATOR
Intervention: 6-Fr standard sheath
Number of subjects: 200
Study 30993313 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XL (2000 mg daily for 12 months)
Number of subjects: 68
Study 30993313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 29979390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine at 120 mg/m biweekly
Number of subjects: 37
Study 29979390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine at 140 mg/m biweekly
Number of subjects: 37
Study 29979390 — intervention group
Group type: COMPARATOR
Intervention: Standard weekly schedule at 80 to 100 mg/m (not directly tested in this trial)
Number of subjects: 37
Study 27123229 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 120 micrograms daily for 2 months, then 60 micrograms daily for 2 months, then 60 micrograms every 2 days
Number of subjects: 66
Study 27123229 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 5 mg twice a day for 6 months
Number of subjects: 66
Study 24660739 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) using Sonazoid (perflubutane)
Number of subjects: 127
Study 24660739 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced ultrasound
Number of subjects: 127
Study 24660739 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MRI
Number of subjects: 127
Study 22699138 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity for 1 week
Number of subjects: 111
Study 22699138 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced physical activity for 1 week
Number of subjects: 111
Study 22699138 — intervention group
Group type: COMPARATOR
Intervention: Depressed participants
Number of subjects: 111
Study 22699138 — intervention group
Group type: COMPARATOR
Intervention: Persons with SSI‐8
Number of subjects: 111
Study 22699138 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 111
Study 22699138 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher general fitness
Number of subjects: 111
Study 19542997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 56
Study 19542997 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 56
Study 17305893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 6 hours later (n=225)
Number of subjects: 450
Study 17305893 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 36-48 hours later (n=225)
Number of subjects: 450
Study 17305893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 6 hours later
Number of subjects: 450
Study 17305893 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 200 mg orally followed by vaginal misoprostol 800 micrograms 36-48 hours later
Number of subjects: 450
Study 15341547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Health Care Clinic (CHCC) group outpatient model
Number of subjects: 294
Study 12137213 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 7
Study 12137213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9864835 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TNFR55-IgG1 0.01 mg/kg
Number of subjects: 218
Study 9864835 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TNFR55-IgG1 0.05 mg/kg
Number of subjects: 218
Study 9864835 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TNFR55-IgG1 0.1 mg/kg
Number of subjects: 218
Study 9864835 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TNFR55-IgG1 0.5 mg/kg
Number of subjects: 218
Study 9864835 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TNFR55-IgG1 20 mg biweekly
Number of subjects: 218